News
RDY
13.24
+2.24%
0.29
Dr. Reddy’s Divests Svaas Wellness Subsidiary in Small April 2026 Deal
TipRanks · 22h ago
Dr. Reddy’s agrees to sell Svaas Wellness to Enspirit for INR 2.23 crore
Reuters · 22h ago
Weekly Report: what happened at RDY last week (0330-0403)?
Weekly Report · 2d ago
Dr. Reddy’s Head-Europe Generics Patrick Rudolf Aghanian files initial beneficial ownership statement
Reuters · 04/01 17:05
Dr. Reddy’s files Form 3 for North America CEO Milan Kalawadia
Reuters · 04/01 16:43
Dr Reddy’s files Form 3 for CEO-Global Generics Motupalli Venkata Ramana
Reuters · 04/01 15:53
Dr. Reddy’s files Form 3 as CEO Erez Israeli reports no beneficial ownership
Reuters · 04/01 15:29
Dr Reddy’s files Form 3 as Sushrut Kulkarni named global head, IPDO
Reuters · 04/01 15:27
Dr Reddy's CIO Phanimitra B files initial beneficial ownership statement
Reuters · 04/01 13:41
Dr Reddy’s CFO Mannam Venkata Narasimh­am files initial beneficial ownership statement
Reuters · 04/01 13:40
Dr Reddy’s files Form 3 beneficial ownership for CEO-API and Services Deepak Sapra
Reuters · 04/01 13:39
Dr. Reddy’s Labs director Alpna Seth files initial beneficial ownership statement
Reuters · 04/01 10:54
Novo cuts Ozempic, Wegovy prices in India amid generic threat
Seeking Alpha · 03/31 14:27
Weekly Report: what happened at RDY last week (0323-0327)?
Weekly Report · 03/30 10:16
Dr. Reddy's Laboratories files Form 3 initial beneficial ownership statement; director Wan Penny Chan reports no securities beneficially owned
Reuters · 03/27 12:39
Dr. Reddy’s Laboratories files Form 3; director Kodumudi Pranatharthi Haran Krishnan reports no securities beneficially owned
Reuters · 03/27 12:38
Dr. Reddy’s Laboratories files initial beneficial ownership statement; director Arun Madhavan Kumar reports no securities beneficially owned
Reuters · 03/27 12:37
Dr. Reddy’s Allots Equity Shares Under ESOP on March 26, 2026
TipRanks · 03/26 11:43
Dr. Reddy’s Tightens Insider-Information Disclosure Code After Board Approval
TipRanks · 03/24 15:48
Dr. Reddy’s Schedules May 12 Board Meeting to Approve FY 2026 Results, Closes Trading Window
TipRanks · 03/23 14:24
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.